Latest Cell Therapy News

AdAlta Limited has bolstered its leadership team and progressed its 'East to West' cellular therapy strategy alongside its lead drug candidate AD-214, despite a tightening cash position. The company’s recent non-binding term sheet and new clinical data signal promising momentum in its biotech pipeline.

Imugene Limited reports durable patient responses in multiple cancer immunotherapy trials and strengthens its financial position with a $46 million convertible note deal and a substantial R&D tax refund.

Imugene Limited has secured A$20 million through convertible notes as part of a broader A$46 million capital raise, aiming to advance its promising immuno-oncology pipeline.

Orthocell Limited has reported a third consecutive quarter of record revenue, driven by strong sales growth and strategic market expansions, including a key US FDA submission for its nerve repair product Remplir™.

Mesoblast has raised A$260 million through a global private placement to fund the US commercial launch of its FDA-approved cell therapy Ryoncil® and accelerate clinical development in chronic low back pain.